Eurasian Hematology-Oncology Group

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Eurasian Hematology-Oncology Group

http://www.ehog.net/

XV Eurasian Hematology-Oncology Congress - EHOC 2024
Leukemia Lymphoma Myeloma MDS and MPN Benign Hematology Videos
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Leukemia Lymphoma Myeloma MDS and MPN Benign Hematology Videos
8th Eurasian Hematology Oncology Summit
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Palliative & Supportive Care COVID-19 Basic Science Leukemia Lymphoma Myeloma MDS and MPN Benign Hematology Lung Business
7th Eurasian Hematology Oncology Summit
COVID-19 Leukemia Lymphoma Myeloma MDS and MPN
Xth Eurasian Hematology-Oncology Congress
Breast Lung Hematologic Oncology Gastrointestinal Genitourinary General Oncology Sarcoma Skin Head & Neck
Events

Playback speed

10 seconds

TKI Discontinuation in CML: Defining Eligibility Criteria and Predictors of Success

By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Mohamed A. Yassin

22 views

September 25, 2024

0 Comments

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Expert Case Review: A Treatment Option for Adult Patients With Stage…

Feat. A. Whiteley

Leukemia

New

Pediatric ALL: Etiology, Diagnosis and Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

O. TüFekçI GüRocak

13 views

New

CML Case Discussion: Elderly Patients not Meeting ELN Milestones

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Isam Sharif

6 views

New

CLL Case: Acquired Del(17p) at Relapse

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Özer Çerme

New

ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Ozsoy

Novel Agents in the Treatment of R/R CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

34 views

Venetoclax-Based Regimens in AML: Understanding Resistance and Devel…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

84 views

Targeted Therapies in AML With a Focus on FLT3 Inhibitors

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

26 views

A Clinical Case of Extranodal MZL of the Palatum Durum After CLL/SLL…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Ridova

6 views

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

118 views

Ph+ ALL Management: Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Koruk

11 views

AML Case Discussion: FLT3-ITD+ High-Risk Disease

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Hindilerden

17 views

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With …

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

37 views

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

17 views

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

22 views

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

11 views

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

138 views

Management of R/R AML: Treatment Options and Case Insights

XV Eurasian Hematology-Oncology Congress - EHOC 2024

V. Bonuomo

37 views

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

558 views

Practical Approach to MRD Monitoring in AML: Assessing Treatment Eff…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

90 views

Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Hoelzer

27 views

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

35 views

CLL Case Discussion: First Line Treatment Strategies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Ortaboz

49 views

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

184 views

CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Erdogan

11 views

The Importance of MRD in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

137 views

Management of AML in Older Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

192 views

Current Approaches to Managing T-Cell ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

19 views

TKI Toxicity Management in CML: A Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Alshurafa

19 views

Management of Persistently MRD+ ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Odabasi Giden

27 views

Debates in AML: 3+7 is the SOC Induction Therapy for AML

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Uzay

51 views

Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-An…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Sarici

24 views

Current Options for Finite-Duration Therapy With BTKis in CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

148 views